ACC.24 - Javed Butler shares the findings of the EMPACT-MI trial, in which empagliflozin had no effect on the primary endpoint in patients with acute MI but significant effect on HF hospitalizations.
Beneficial effect of the SGLT2 inhibitor empagliflozin on HF-hospitalizations after acute MI
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Restart
Resume
Transcript
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
closeShare this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Javed Butler, MD, is the President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health in Dallas, TX, US. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MI, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of EMPACT-MI trial
Release date: 6 april 2024
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
ACC.24 - Javed Butler shares the findings of the EMPACT-MI trial, in which empagliflozin had no effect on the primary endpoint in patients with acute MI but significant effect on HF hospitalizations.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Javed Butler, MD, is the President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health in Dallas, TX, US. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MI, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of EMPACT-MI trial
Release date: 6 april 2024
Presenters
Facebook Comments